Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: Three efficacy studies

International Clinical Psychopharmacology

Volumn 12, Issue SUPPL. 2, 1997, Pages

  Freeman, Hugh L ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Acute schizophrenia; Amisulpride; Extrapyramidal symptoms; Negative symptoms; Positive symptoms

Indexed keywords

AMISULPRIDE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; CONFERENCE PAPER; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; RATING SCALE; RECEPTOR AFFINITY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; FLUPENTHIXOL; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; NEUROLOGIC EXAMINATION; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; SULPIRIDE; TREATMENT OUTCOME;

EID: 0030743114     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199705002-00004     Document Type: Conference Paper

References (21)

1. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Association.
2. Andreasen N, Olsen S (1982) Negative versus positive schizophrenia: definition and validation. Arch Gen Psychiatry 39:789-794.
3. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
4. Bech P (1981) Rating scales for affective disorders: their validity and consistency. Acta Psychiatr Scand 64 (suppl 295): 1-101.
5. Boyer P, Lecrubier Y, Puech AJ, et al. (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166:68-72.
6. Carpenter WT, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11:440-452.
7. Guy W (Ed) (1976) ECDEU: Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Environment and Welfare.
8. Hillert A, Philipp M, Gattaz WF, et al. (1994) Amisulpride versus flupenthixol in the treatment of schizophrenia with predominant positive symptomatology: a controlled double-blind study [abstract]. Neuropsychopharmacology 10 (suppl 3, part 2):31S.
9. Kay S, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
10. Lingjaerde O, Ahlfors UG, Bech P, et al. (1987) The UKU side effect rating scale. Acta Psychiatr Scand 76 (suppl 334):81-101.
11. Loo H, Poirier-Littré MF, Théron M, et al. (1997) Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170:18-22.
12. Möller HJ, Boyer P, Fleurot O, Rein W, and the Prod-aslp Study Group (1997) Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison to haloperidol. Psychopharmacology (in press).
13. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152:1444-1449.
14. Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10:799-812.
15. Paillère-Martinot ML, Lecrubier Y, Martinot JL, et al. (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152:130-133.
16. 3 dopamine receptor antagonist activity and limbic selectivity. J PET 180:73-82.
17. Puech A, Fleurot O, Rein W, et al. (1996) Amisulpride in the treatment of acute exacerbations of subchronic or chronic schizophrenia: a dose-range finding study [abstract]. Eur Psychiatry 11 (suppl 4):280S.
18. 3 receptor antagonist with both presynaptic and limbic selectivity. J PET 180:83-97.
19. Schotte A, Janssen PFM, Gommeren W, et al. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73.
20. Simpson G, Angus JA (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 46 (suppl 212):11-19.
21. 2 receptor. Eur J Pharmacol 225:331-337.